How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,354 results for

aspirin and gastrointestinal bleeding

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. A risk-scoring model for the prediction of delayed bleeding after colorectal endoscopic submucosal dissection. (Abstract)

; 95% confidence interval [CI], 1.96-21.42; P = .002), large tumor (≥30 mm) (OR, 2.10; 95% CI, 1.01-4.40; P = .048), and use of antiplatelet agents except for aspirin alone (OR, 4.04; 95% CI, 1.44-11.30; P = .008). These 3 factors were incorporated into a risk-scoring model for prediction of delayed bleeding. As the score based on this system increased, the incidence of delayed bleeding increased in the validation cohort.The risk-scoring model incorporating tumor location, tumor size, and use (...) of antiplatelet agents can quantitatively predict the risk of delayed bleeding after colorectal ESD.Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

2018 Gastrointestinal endoscopy

142. The role of endoscopy in the patient with lower GI bleeding

The role of endoscopy in the patient with lower GI bleeding GUIDELINE The role of endoscopy in the patient with lower GI bleeding This is one of a series of statements discussing the use of GI endoscopy in common clinical situations. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) prepared this text. In preparing this document, a search of the medical literature pertaining to this topic published between January 1990–March 2013 was performed (...) bleeding accounts for 20% to 65% of acute LGIB epi- sodes. 24-26 Clinically signi?cant bleeding occurs in 3% to 15% of patients with colon diverticula, 27,28 usually as a Copyrightª 2014 by the American Society for Gastrointestinal Endoscopy 0016-5107/$36.00 http://dx.doi.org/10.1016/j.gie.2013.10.039 www.giejournal.org Volume 79, No. 6 : 2014 GASTROINTESTINAL ENDOSCOPY 875result of trauma to the vasa recta at the neck or dome of thediverticulum. 11,29 Nonsteroidalanti-in?ammatorydrugs (NSAIDs

2014 American Society for Gastrointestinal Endoscopy

143. Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU

Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU (REVISE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02290327 Recruitment Status : Completed First Posted : November 14, 2014 Last Update Posted : February 8, 2016

2014 Clinical Trials

144. A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC) A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

145. A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients. (Abstract)

was 1.45, 1.31, 1.50, 1.53, and 1.62; for upper GI bleeding: 1.76, 1.62, 1.96, 1.82, and 2.38; and for gastroesophageal reflux disease: 1.54, 1.41, 1.89, 1.67, and 1.91 for NSAIDs, COX-2 selective inhibitors, low-dose aspirin, antiplatelet drugs, and anticoagulants, respectively (all statistically significant: P < 0.001). Polypharmacy with NSAIDs and antithrombotic drugs increased the risk of upper GI injuries compared with single-drug therapy. The injury risk was also increased by lifestyle-related (...) A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients. We aimed to identify the adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and antithrombotics on the upper gastrointestinal (GI) mucosa in a clinical setting as a case-control study using a large-scale medical database in Japan.We evaluated

2018 Journal of gastroenterology

146. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. (Abstract)

., ibuprofen 600-800 mg t.d.s. or naproxen 375-500 mg b.d. plus esomeprazole, and low-dose aspirin or corticosteroids if already prescribed. Clinically significant GI events (CSGIE-bleeding, obstruction, perforation events from stomach downwards or symptomatic ulcers) and iron deficiency anaemia (IDA) were adjudicated blindly.Mean treatment and follow-up durations were 20.3 and 34.1 months. While on treatment or 30 days after, CSGIE occurred in 0.34%, 0.74% and 0.66% taking celecoxib, ibuprofen (...) serological status had no influence.Arthritis patients taking NSAIDs plus esomeprazole have infrequent clinically significant gastrointestinal events. Co-prescribed with esomeprazole, celecoxib has better overall GI safety than ibuprofen or naproxen at these doses, despite treatment with low-dose aspirin or corticosteroids.© 2018 John Wiley & Sons Ltd.

2018 Alimentary Pharmacology & Therapeutics Controlled trial quality: predicted high

147. Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients

-inflammatory drug use in the past week (including aspirin), renal failure (creatinine clearance <30 mL/min), platelet count <100,000/microL, history of gastrointestinal bleeding within the last 6 months, presence of coexisting inflammatory disease, cancer, active bacterial or fungal infection, bleeding history, oral anticoagulant therapy and allergy to aspirin Contacts and Locations Go to No Contacts or Locations Provided More Information Go to Layout table for additonal information Responsible Party (...) Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2017 Clinical Trials

148. Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer

2) Active gastrointestinal bleeding Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03170115 Contacts Layout table for location contacts Contact: Alessandra Marins 00552132076666 Contact: Juliana Ominelli, MD 5521988734435 Locations Layout table (...) Keywords provided by Instituto Nacional de Cancer, Brazil: Rectal Cancer Total neoadjuvant therapy Induction chemotherapy Aspirin colorectal cancer Additional relevant MeSH terms: Layout table for MeSH terms Adenocarcinoma Rectal Neoplasms Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Intestinal

2017 Clinical Trials

149. Appropriateness of Aspirin Use in Medical Outpatients

to the US Preventive Services Task Force (USPSTF) and European Society of Cardiology (ESC) guidelines. Physicians will complete a standardized survey form to collect information on patient clinical characteristics, cardiovascular risk factors, medical history, clinical examination, laboratory test results, and medications. Patients' risk factors for colorectal cancer and gastrointestinal bleeding will also be questioned. ASSOS registry will be the largest and most comprehensive study in Turkey (...) Appropriateness of Aspirin Use in Medical Outpatients Appropriateness of Aspirin Use in Medical Outpatients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Appropriateness of Aspirin Use in Medical

2017 Clinical Trials

150. Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients

] The percentage of patients of a data set who survive without distant metastasis after a defined period of time from pathologic diagnosis Secondary Outcome Measures : Overall survival [ Time Frame: 5 years after diagnosis ] The percentage of patients of a data set who survive after a defined period of time from pathologic diagnosis Aspirin-related toxicities [ Time Frame: 5 years after diagnosis ] Incidence of aspirin-related toxicities such as gastrointestinal bleeding and liver dysfunction Eligibility (...) Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Aspirin Improve Survival

2017 Clinical Trials

151. An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

. History of gastroesophageal reflux disease, dyspepsia, protracted nausea or chronic diarrhea. History of upper gastrointestinal ulcer disease within 6 months or current symptomatic or recent gastrointestinal disease that could impact absorption of study treatment. Abnormal renal profile and/or hematuria (if male) within 3 months of study start. History or evidence of abnormal bleeding and/or coagulation disorder and/or evidence of coagulopathy, prolonged or unexplained clinically significant bleeding (...) An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

152. Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex

and would maintain until the end of the trial Exclusion Criteria: Subependymal Giant Cell Astrocytoma and requires immediate surgery; a history of intracranial surgery within 6 months; epilepsy caused by improper use of drugs; patients treated with aspirin had severe or intolerant side effects, including gastrointestinal ulcer, bleeding, aspirin allergy, and other conditions; psychogenic seizures; severe renal dysfunction and infection pregnant women and lactating women not regular follow-up other (...) Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2017 Clinical Trials

153. The Effect of a Probiotic Strain on Aspirin-induced GI Damage.

within endurance sports) Willing to abstain from any other probiotic products and/or medication known to alter gastrointestinal function throughout the participation of the trial Exclusion Criteria: Abdominal surgery which, as judged by the investigator, might affect the GI function (except appendectomy and cholecystectomy) History of peptic ulcer disease Any known bleeding disorder Allergy to Aspirin History of H. pylori disease Resting diastolic blood pressure ≥ 90 mmHg Resting systolic blood (...) measured as the area-under-the-curve of the capsule endoscopy mucosal total ulcer number between Visit 2 (randomization) and Visit 7 (end of treatment). Pain module score of the GSRS questionnaire [ Time Frame: 8 weeks ] The effect of 8 weeks oral supplementation of probiotic strain versus placebo on gastrointestinal symptoms when co-administered to a 6 week Aspirin challenge measured as the area-under-the-curve of pain module score of the GSRS questionnaire between Visit 2 (randomization) and Visit 7

2017 Clinical Trials

154. Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation Full Text available with Trip Pro

Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation Aspirin, when used with concurrent anticoagulation, increases the risk of gastrointestinal bleeding (GIB). Therefore, multisociety guidelines recommend prophylactic proton-pump inhibitors (PPIs) for patients receiving aspirin and anticoagulation. We aimed to determine rates and predictors of adherence to these recommendations.All adult inpatients discharged (...) from the hospital on aspirin and anticoagulation from July 2009 to June 2014 were retrospectively evaluated for PPI prescription on discharge instructions. We used univariate and multivariate logistic regression to test for predictors of PPI prescription.A total of 2422 patients were discharged on aspirin and anticoagulation; the mean age was 68 years and 53.2% were male; 42.2% were prescribed a PPI at discharge. On univariate analysis, factors associated with discharge PPI prescription included

2017 Therapeutic advances in gastroenterology

155. Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran Full Text available with Trip Pro

Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran Aspirin is one of the certified medicines commonly used for the secondary prevention of myocardial infarction (MI). Aspirin side effects and gastrointestinal bleeding, in particular, have arisen debates on its use for the primary prevention of MI. The present research evaluates the cost-effectiveness of the use of aspirin in the primary prevention of MI (...) among Iranian men with average cardiovascular disease (CVD) risk, using Markov modeling technique. The incremental cost-effectiveness ratios (ICERs) estimated to be 864 USA dollars (USD) per quality-adjusted life years (QALY) gained and 782 USD per life years gained (LYG) for each patient in the base-case scenario (public tariffs and no discounting). This research proves cost-effectiveness of the use of aspirin in the primary prevention of MI in targeted population, since the assessed ICERs

2017 Research in pharmaceutical sciences

156. Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke Full Text available with Trip Pro

(experimental group) than that in aspirin alone group. No significant difference was found in the function of the coagulation system, suggesting that BPS plus aspirin treatment did not increase the risk of bleeding. Serious adverse events did not occur in both groups. Facial flushing (one case) and mild gastrointestinal reaction (one case) were found in the treatment group without influencing treatment. CONCLUSIONS In our trial involving patients with acute cerebral infarction, BPS plus aspirin (...) was not found to be superior to aspirin in reducing the recurrence of cerebral infarction or death. However, BPS plus aspirin treatment could improve renal function and neurological function without increasing the risk of bleeding.

2017 Medical science monitor : international medical journal of experimental and clinical research

157. Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. (Abstract)

with deep venous thrombosis and 5 with pulmonary embolism). The incidence of gastrointestinal bleeding or ulceration of 0.3% (95% CI, 0% to 0.5%) in the 81-mg aspirin group was slightly, but not significantly (p = 0.66), lower than the 0.4% (95% CI, 0.2% to 0.6%) in the 325-mg aspirin group. The incidence of acute periprosthetic joint infection was 0.2% (95% CI, 0% to 0.4%) in the 81-mg aspirin group compared with 0.5% (95% CI, 0.2% to 0.7%) in the 325-mg aspirin group (p = 0.28). The 90-day mortality (...) gastrointestinal side effects.In a prospective, crossover study, we analyzed 4,651 primary total joint arthroplasty cases performed from July 2013 to June 2015. For 4 weeks, 3,192 patients received enteric-coated 325-mg aspirin twice daily (the 325-mg aspirin group) and 1,459 patients received 81-mg aspirin twice daily (the 81-mg aspirin group). There were no significant differences (p > 0.05) in sex, body mass index, or Charlson Comorbidity Index between the two patient populations. Recorded complications

2017 The Journal of Bone and Joint Surgery. American Volume

158. Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis

with blood sugar levels lower body weakness or reliance on supportive devices for walking (as indicated through EDSS) counter indications to aspirin use: history of confirmed peptic ulcer, gastrointestinal or sever gynecological bleeding; tarry stool or fecal occult blood; syndrome of asthma, rhinitis or nasal polyps Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact (...) Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Aspirin as a Pre-Treatment

2017 Clinical Trials

159. Study of Aspirin in Patients With Vestibular Schwannoma

for themselves will not be eligible to participate in this study. Ability to swallow tablets. Exclusion Criteria: Inability to perform volumetric measurements of vestibular schwannoma(s). Inability to tolerate MRI with contrast. Daily use of aspirin within the last two months. Occasional use of aspirin for pain relief is not exclusionary. Known allergy to aspirin. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of aspirin. Pregnant or lactating (...) Study of Aspirin in Patients With Vestibular Schwannoma Study of Aspirin in Patients With Vestibular Schwannoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study of Aspirin in Patients With Vestibular

2017 Clinical Trials

160. A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients.

, clopidogrel, prasugrel, ticagrelor, or ticlopidine). Any other invasive malignancies (with the exclusion of basal cell carcinoma or cutaneous squamous cell carcinoma) diagnosed during the last 5 years before randomization. Past history of any other invasive CRC than the one the patient is currently being treated for Alcohol or drug abuse. Prior history of gastro-intestinal bleeding or hemorrhagic diathesis (e.g. hemophilia). Erosive-ulcerative lesions in the gastrointestinal tract. History of erosive GERD (...) Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Metformin Aspirin Hypoglycemic Agents Physiological Effects of Drugs Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>